Sucha Sudarsanam

Thermo Fisher Scientific (United States) — United States

Medicine · Health Sciences

16h-index10.5kcitations40works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(8), Protein Structure and Dynamics(5), Lung Cancer Treatments and Mutations(5), Enzyme Structure and Function(5), Computational Drug Discovery Methods(4)

Publications40 total

Machine Learning Approach to Estimating ECOG PS for a Multiple-Myeloma Cohort from Real World Data
Blood·2023· 1 cited
Real-world data analysis of PD-L1 expression and overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)
Annals of Oncology·2019· 1 cited
Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases
Modern Pathology·2019· 78 citedOpen Access
Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States
Blood·2018
A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies
Journal of Clinical Pathology·2018· 63 citedOpen Access
P3.13-03 Real-World Anaplastic Lymphoma Kinase Testing Practices: Results from a Survey in the United States
Journal of Thoracic Oncology·2018
Association between microsatellite instability and <i>BRAF</i>, <i>TP53</i>, <i>PTEN</i>, and <i>KRAS</i> mutations in colorectal cancer.
Journal of Clinical Oncology·2018
Identifying new biomarkers and targeted molecules for immunotherapy using targeted RNA next generation sequencing.
Journal of Clinical Oncology·2018
Mismatch repair deficiency testing for immune checkpoint therapy: Immunohistochemistry vs microsatellite instability.
Journal of Clinical Oncology·2018
Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
Breast Cancer Research and Treatment·2018· 40 citedOpen Access
Correlation of <i>MET</i> gene amplification and <i>TP53</i> mutation with PD-L1 expression in non-small cell lung cancer
Oncotarget·2018· 53 citedOpen Access
IDH1 and IDH2 : Founding or Progressor Mutations in Myeloid Neoplasms
Blood·2017· 2 cited
Clonal Hematopoiesis in Normal Individuals Is Not Random and Likely Reflects Early MDS
Blood·2017
FLT3 Mutation in Acute Myeloid Leukemia: Primary or Secondary Mutation?
Blood·2017
Abstract 4015: A comparative study of PD-L1 IHC 22C3 and 28-8 FDA-approved diagnostic assays in cancer
Cancer Research·2017· 3 cited
Abstract 5618: Correlation between MET gene amplification and TP53 mutation in upregulating PD-L1 expression in EGFR wild-type lung cancer
Cancer Research·2017
Expression of PD-L1 in colorectal cancer that lack mutations in RAS or TP53 genes.
Journal of Clinical Oncology·2017· 9 cited
<i>BRAF</i> mutation and PD-L1 expression in melanoma: Comparison between multiple PD-L1 IHC clones and <i>BRAF</i> mutation evalutated by FDA-approved kits versus NGS.
Journal of Clinical Oncology·2017· 1 cited
Biomarkers
Methods in molecular biology·2012· 4 cited
Translational Biology Approach to Identify Causative Factors for Rare Toxicities in Humans and Animals
Current Drug Discovery Technologies·2012· 2 cited
page 1 of 2Next →

Frequent Co-authors

Maher Albitar(14), Shiping Jiang(10), Vincent Funari(10), Sally Agersborg(10), Wanlong Ma(9), Forrest Blocker(8), Wayne Chen(7), Carl J. March(6), Jonathan Bingham(5), Dale E. Johnson(5), Vladislav Chizhevsky(5), Tony Hunter(4), Ivan De Dios(4), Gerard Manning(3), Gregory D. Plowman(3), Lawrence M. Weiss(3), Jennifer Hummel(3), Elena T. Chan(2), Dennis P. O’Malley(2), Cory Batenchuk(2)